Veracyte is a pioneering genomic diagnostics company. The Company is developing molecular tests designed to improve the diagnostic accuracy of cytology samples, thereby helping to increase the utility of these minimally invasive procedures as an alternative to surgical biopsy. 

Veracyte consistently brings to bear evidence that is unprecedented in genomic tests, thereby changing today's clinical practice standards.

Type
Public
HQ
South San Francisco, US
Founded
2008
Size (employees)
216 (est)
Veracyte was founded in 2008 and is headquartered in South San Francisco, US
Report incorrect company information

Key People/Management at Veracyte

Bonnie Anderson

Bonnie Anderson

Co-Founder & CEO
Shelly D. Guyer

Shelly D. Guyer

CFO
Richard Lanman

Richard Lanman

Chief Medical Officer
Giulia C. Kennedy

Giulia C. Kennedy

Chief Scientific Officer
Chris Hall

Chris Hall

Chief Commercial Officer
Robert Monroe

Robert Monroe

VP, Laboratory Operations & Medical Director

Veracyte Office Locations

Veracyte has offices in South San Francisco and Austin
South San Francisco, US (HQ)
300 6000 Shoreline Ct
Austin, US
100 12357 Riata Trace Pkwy
Show all (2)
Report incorrect company information

Veracyte Financials and Metrics

Veracyte Financials

Veracyte's revenue was reported to be $71.95 m in FY, 2017
USD

Revenue (Q1, 2018)

20 m

Gross profit (Q1, 2018)

12.2 m

Gross profit margin (Q1, 2018), %

60.7%

Net income (Q1, 2018)

(9.2 m)

EBIT (Q1, 2018)

(9 m)

Market capitalization (14-Jun-2018)

299.5 m

Closing share price (14-Jun-2018)

8.7

Cash (31-Mar-2018)

27.2 m

EV

297.4 m
Veracyte's current market capitalization is $299.5 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

21.9 m38.2 m49.5 m65.1 m72 m

Revenue growth, %

75%30%31%

Cost of goods sold

12.6 m16.6 m21.5 m25.5 m28.2 m

Gross profit

9.3 m21.6 m28 m39.6 m43.8 m
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Revenue

11.2 m11.9 m12.3 m13.6 m14.7 m18.6 m16.4 m18.4 m20 m

Cost of goods sold

4.6 m5.1 m5.6 m6.3 m6.3 m6.4 m6.3 m7 m7.9 m

Gross profit

6.7 m6.8 m6.7 m7.3 m8.4 m12.2 m10.1 m11.4 m12.2 m

Gross profit Margin, %

59%57%54%54%57%66%62%62%61%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

71.2 m35 m39.1 m59.2 m33.9 m

Accounts Receivable

1.1 m3.1 m3.5 m8.8 m12.7 m

Inventories

1.5 m1.2 m1.5 m2.1 m

Current Assets

76.4 m43.3 m47.9 m73.6 m53.9 m
Quarterly
USDQ1, 2015Q2, 2015Q1, 2018

Cash

25.8 m51 m27.2 m

Accounts Receivable

13.2 m

Current Assets

33.7 m60.7 m47 m

PP&E

4.1 m4.2 m9.2 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(25.6 m)(29.4 m)(33.7 m)(31.4 m)(31 m)

Depreciation and Amortization

999 k1.2 m2.3 m3.5 m3.8 m

Accounts Payable

3.3 m1.9 m(3.5 m)(1.4 m)1.7 m

Cash From Operating Activities

(19.2 m)(27.6 m)(27 m)(28 m)(23.9 m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Net Income

(7.6 m)(9.1 m)(8.9 m)(10.1 m)(11.2 m)(5.6 m)(8.2 m)

Accounts Payable

5.6 m7.2 m8.5 m8.6 m6.9 m2.7 m6.6 m4.3 m2.7 m3.1 m2.6 m2.3 m
USDY, 2018

EV/EBIT

-33.2 x

Financial Leverage

2.4 x
Show all financial metrics

Veracyte Operating Metrics

FY, 2016

Facilities

2

Patents Issued

13

Products

3
Show all operating metrics
Report incorrect company information

Veracyte Online and Social Media Presence

Embed Graph
Report incorrect company information

Veracyte News and Updates

Report incorrect company information